PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma
Advanced Science · 2026
DOI: 10.1002/advs.202515207 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Advanced Science, 2026. Verfasst von Dijian Shen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology Surgery, Hangzhou Institute of Medicine, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, Zhejiang, C…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Positive Regulatory Domain I-Binding Factor 1, Neoadjuvant Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China, National Key R&D Program of China.
Abstract (Originalsprache)
The mechanisms underlying resistance to neoadjuvant immunotherapy and chemoradiotherapy (nICRT) in locally advanced esophageal squamous cell carcinoma (ESCC) remain poorly understood. Through a single‐arm phase II trial ( n = 22) with 44.4‐month median follow‐up, we observed a significant survival disparity: patients achieving major pathologic response (MPR) exhibited superior 3‐year event‐free survival (EFS) and overall survival (OS), with no recurrence in MPR patients versus 71.4% recurrence in non‐major pathological response (NMPR) patients (HR = 17.69, 95% CI 2.25–139.20, p = 0.0063). Integrating single‐cell RNA/TCR sequencing and functional validation, we identified a PRDM1+ malignant cell subcluster enriched in NMPR patients and associated with treatment resistance. These cells exhibit strong lipid peroxidation characteristics, a state linked to the transcriptional activation of CTSB and MFSD12 mediated by PRDM1. This state renders the PRDM1+ malignant cell cluster more susceptible to ferroptosis induction. PRDM1+ cells further recruited immunosuppressive regulatory T cells (Tregs) through IL1A‐IL1R2 interactions and activated lipid‐metabolizing TREM2+ macrophages via CD47‐SIRPA signaling, fostering an immune‐evasive microenvironment. Conversely, MPR patients displayed expanded cytotoxic T‐effector clones with enhanced tumor‐killing capacity. Our findings identify PRDM1 as a key factor associated with nICRT resistance and suggest that targeting ferroptosis pathways or disrupting PRDM1+ cell‐mediated immune suppression may represent a viable strategy in ESCC. Clinical trial registration number: NCT03940001.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Oncology Surgery, Hangzhou Institute of Medicine, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
- Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.
- United Laboratory of Frontier Radiotherapy Technology of Sun Yat-Sen University and Chinese Academy of Sciences Ion Medical Technology Co., Ltd., Guangzhou, Guangdong, China.
- Department of Experimental Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
- Department of Biochemistry, School of Medicine, Shenzhen Children's Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, China.
- Department of Radiation Oncology, Hangzhou Institute of Medicine, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
ORCID-Profile: Dijian Shen, Xuefei Liu, Ming Chen
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- National Natural Science Foundation of China
- National Key R&D Program of China
- United Laboratory of Frontier Radiotherapy Technology of Sun Yat-sen University & Chinese Academy of Sciences Ion Medical Technology Co., Ltd, and Cancer Innov…
- Key R&D Program of Zhejiang
- National Key Research and Development Program of China
Zitieren
APA
Shen, D., Li, R., She, Y., Liu, X., Huang, Y., Ji, Y., Chen, K., Song, Z., Chen, R., Li, X., Zhao, Q., Chen, Q., & Chen, M. (2026). PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma. Advanced Science. https://doi.org/10.1002/advs.202515207
Vancouver
Shen D, Li R, She Y, Liu X, Huang Y, Ji Y, et al. PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma. Advanced Science. 2026. doi:10.1002/advs.202515207
BibTeX
@article{Shen2026,
author = {Shen, Dijian and Li, Rui and She, Yong and Liu, Xuefei and Huang, Yuanyang and Ji, Yongling and Chen, Keying and Song, Zhengbo and Chen, Runzhe and Li, Xuan and Zhao, Qi and Chen, Qixun and Chen, Ming},
title = {PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202515207}
}
EUVIMED